A dynamic model of hepatitis B virus with drug-resistant treatment

Dong-Mei Li; Bing Chai; Dong-Mei Li; Bing Chai

doi:10.3934/math.2020303

AIMS Mathematics

2020, Volume 5, Issue 5: 4734-4753. doi: 10.3934/math.2020303

Previous Article Next Article

Research article

A dynamic model of hepatitis B virus with drug-resistant treatment

Dong-Mei Li ^,,
Bing Chai

College of Science, Harbin University of Science and Technology, Harbin 150080, China

Received: 18 March 2020 Accepted: 11 May 2020 Published: 29 May 2020
MSC : 34K20, 92B05, 92D25

In this paper, the problem of reducing the effectiveness of drug resistance treatment due to mutation of hepatitis B virus is investigated, a model of hepatitis B virus with drug resistance treatment is established, and the existence conditions of four equilibrium points in the model are provided. The effect of drug resistance caused by virus mutation on drug treatment is simulated. It is found that drug efficacy decreases with the increase in mutation rate. Without considering the value of mutation rate, the continuous usage of drugs can meet the clinical treatment standard, while stopping treatment will cause the virus to rebound.
- drug resistance,
- dynamics model of hepatitis B virus,
- equilibrium point,
- stability,
- numerical simulation
Citation: Dong-Mei Li, Bing Chai. A dynamic model of hepatitis B virus with drug-resistant treatment[J]. AIMS Mathematics, 2020, 5(5): 4734-4753. doi: 10.3934/math.2020303

Related Papers:

Abstract

In this paper, the problem of reducing the effectiveness of drug resistance treatment due to mutation of hepatitis B virus is investigated, a model of hepatitis B virus with drug resistance treatment is established, and the existence conditions of four equilibrium points in the model are provided. The effect of drug resistance caused by virus mutation on drug treatment is simulated. It is found that drug efficacy decreases with the increase in mutation rate. Without considering the value of mutation rate, the continuous usage of drugs can meet the clinical treatment standard, while stopping treatment will cause the virus to rebound.

References

[1]	X. Fan, X. D. Lin, X. H. Cen, Research advances in drug resistance to nucleos(t)ide analogues in treatment of chronic hepatitis B, J. Clin. Hepatol., 31 (2015), 611-613.
[2]	L. Boglione, A. De Nicolò, J. Cusato, et al. Entecavir plasma concentrations are inversely related to HBV-DNA decrease in a cohort of Treatment-Naïve patients with chronic hepatitis B, Inter. J. Antimicrob. Agents, 48 (2016), 324-327. doi: 10.1016/j.ijantimicag.2016.05.016
[3]	S. X. Li, J. L. Liu, W. He, Inhibitory mechanisms of nucleos(t)ide analogs in HBV replication and drug resistance on nucleos(t)ide analog treatment of hepatitis B, Chin. J. Antibiot., 34 (2009), 193-199.
[4]	R. C. Mao, J. M. Zhang, Y. K. Yi, et al. Selection and clearance of entecavir-resistant HBV strains in lamivudine-resistant hepatitis B patient treated with entecavir:A case report, Chin. Hepatol., 2 (2007), 220-223.
[5]	S. Bonhoeffer, R. M. May, G. M. Shaw, et al. Virus dynamics and drug therapy, Proc. Natl. Acad. Sci., 94 (1997), 6971-6976. doi: 10.1073/pnas.94.13.6971
[6]	B. Zhang, G. Tanaka, K. Aihara, et al. Dynamics of an HBV model with drug Resistance under intermittent antiviral therapy, Int. J. Bifurcation Chaos, 25 (2015), 1-12.
[7]	Y. Wang, F. Brauer, J. Wu, et al. A delay-dependent model with HIV drug resistance during therapy, J. Math. Anal. Appl., 414 (2014), 514-531. doi: 10.1016/j.jmaa.2013.12.064
[8]	R. De Man, L. Wolters, F. Nevens, et al. Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection, Hepatology, 34 (2001), 578-582. doi: 10.1053/jhep.2001.26815
[9]	J. Zhang, W. J. Xu, G. Wang, Analysis of lamivudine-resistant mutations in 268 patients with chronic hepatitis B during lamivudine therapy, Chin. J. Health Lab. Technol., 18 (2008), 2343-2344.
[10]	M. Ghany, T. J. Liang, Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B, Gastroenterology, 132 (2007), 1574-1585. doi: 10.1053/j.gastro.2007.02.039
[11]	X. X. LIAO, Theory methods and application of stability, 2 Eds., WuHan: Huazhong University of Science and Technology Press, 2010.
[12]	Z. Y. Ye, Y. Liu, Y. Wu, Stability of a SIQR model with with nonmonotone incidence rate, J. Biomath., 29 (2014), 105-112.
[13]	Y. Cheng, J. Wang, X. Yang, On the global stability of a generalized cholera epidemiological model, J. Biol. Dyn., 6 (2012), 1088-1104. doi: 10.1080/17513758.2012.728635
[14]	S. Y. Chen, D. B. Wang, An uniform persistence of a Lotka-Volterra discrete Predator-Prey system with delays, J. Southwest China Norm. Univ. (Nat. Sci. Ed.), 4 (2003), 14-18.
[15]	L. Min, Y. Su, Y. Kuang, Mathematical analysis of a basic virus infection model with application to HBV infection, Rocky Mt. J. Math., 38 (2008), 1573-1585. doi: 10.1216/RMJ-2008-38-5-1573
[16]	H. P. Zhou, J. Yan, X. J. Chen, et al. Clinical efficacy of entecavir in treatment of patients with chronic hepatitis B, Chin. J. Nosocomiol., 17 (2014), 4237-4239.
[17]	S. M. Zhang, H. H. Ding, H. Q. Ren, et al. Research on entecavir efficacy and plasama concentration in treatment of chronic hepatitis B for 48 weeks, Chin. Hepatol., 20 (2015), 14-17.
[18]	J. Hou, G. Wang, F. Wang, et al. Guideline of prevention and treatment for chronic hepatitis B (2015 Update), J. Clin. Transl. Hepatol., 5 (2017), 297-318. doi: 10.14218/JCTH.2016.00019
[19]	M. Tsuge, E. Murakami, M. Imamura, et al. Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients, J. Gastroenterol., 48 (2013), 1188-1204. doi: 10.1007/s00535-012-0737-2
[20]	C. Z. Hu, The clinical curative effects adefovir dipivoxil and entecavir combined in lamivudine resistance of chronic hepatitis B patients, Guide China Med., 9 (2011), 178-179.
[21]	Y. M. Jiang, J. C. Liang, X. X. Chen, et al. Effective analysis of using entecavir in combination with adefovir dipivoxil for a 48-week of chronic hepatitis B patients with lamivudine-resistance, Int. J. Digest. Dis., 34 (2014), 401.

Reader Comments

Your name:*

Email:*
© 2020 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)